CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
Chicago, Illinois, United States and 66 other locations
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...
Phase 1, Phase 2
Chicago, Illinois, United States and 31 other locations
intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to...
Phase 1, Phase 2
Chicago, Illinois, United States and 8 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
Chicago, Illinois, United States and 55 other locations
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 in patients with CLL/SLL or B-cell NHL who have failed or are intolerant...
Phase 1
Chicago, Illinois, United States and 9 other locations
clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two...
Phase 1, Phase 2
Chicago, Illinois, United States and 20 other locations
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 or CC-99282) i...
Phase 1
Chicago, Illinois, United States and 26 other locations
This study has 2 parts.The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or refractory (r/r) B-cell Non...
Phase 2
Chicago, Illinois, United States and 14 other locations
Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non- ...
Phase 1
Chicago, Illinois, United States and 8 other locations
lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).As of October 2022, no furt...
Phase 1, Phase 2
Chicago, Illinois, United States and 29 other locations
Clinical trials
Research sites
Resources
Legal